Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension

NCT05184335 is registered in ClinicalTrials.gov with Reviva Pharmaceuticals as lead sponsor.

NCT NCT05184335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension
Lead sponsor
Reviva Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
January 24, 2022
Completion date
February 28, 2025
Enrollment
690 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia